Liao Lingxia, Han Guang, Li Yanping, Wang Zhaohua, Liu Dong, Pi Zhengchao
Department of Radiotherapy, Hubei Cancer Hospital, Wuhan 430079, P.R. China.
Exp Ther Med. 2011 May;2(3):551-555. doi: 10.3892/etm.2011.223. Epub 2011 Mar 2.
Recently, a number of clinical trials assessing partial breast irradiation (PBI), in particular accelerated partial breast irradiation, have been conducted in patients with early-stage breast cancer after breast-conserving surgery (BCS) in Europe and the US. By contrast, PBI is rarely performed in Eastern countries. In general, there are many physiological differences between Eastern and Western populations, and whether PBI is suitable for Eastern populations remains uncertain. Moreover, PBI is still in the stage of clinical research, and numerous questions have yet to be resolved. Thus, we designed a PBI trial to explore its feasibility and effectiveness for Eastern patients. According to the study criteria, 12 patients were enrolled between June 2003 and March 2007. Using three-dimensional conformal partial breast irradiation, they received a conventional fraction of 2 Gy/fraction/day, 5 fractions/week, DT60 Gy. According to follow-up data collected in August 2010, the rates of local recurrence and distant metastasis were 0%. The most common adverse reactions included grade 2 radioactive erythema in 2 (17%) cases and pigment deposition in 10 (83%). The results revealed that the patients exhibited good local tumor control, with minor adverse reactions and satisfactory cosmetic results. More samples and long-term observations are required to further assess the validity and feasibility of PBI.
最近，欧洲和美国针对保乳手术（BCS）后的早期乳腺癌患者开展了多项评估部分乳腺照射（PBI）的临床试验，尤其是加速部分乳腺照射。相比之下，PBI在东方国家很少进行。一般来说，东西方人群存在许多生理差异，PBI是否适用于东方人群仍不确定。此外，PBI仍处于临床研究阶段，众多问题尚未解决。因此，我们设计了一项PBI试验，以探索其对东方患者的可行性和有效性。根据研究标准，2003年6月至2007年3月期间共纳入12例患者。采用三维适形部分乳腺照射，他们接受常规分割剂量，即每天2 Gy/次，每周5次，总剂量60 Gy。根据2010年8月收集的随访数据，局部复发率和远处转移率均为0%。最常见的不良反应包括2例（17%）2级放射性红斑和10例（83%）色素沉着。结果显示，患者局部肿瘤控制良好，不良反应轻微，美容效果满意。需要更多样本和长期观察来进一步评估PBI的有效性和可行性。
